REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cell boost shows promise against hard-to-treat lymphomas
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has returned or not responded to prior therapy. The treatment combines donor immune cells (NK cells) with a targeted antibody (mogamulizumab) to help the …
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: John Reneau • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
Virus-Based therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC